Purpose: NC-6300 is a novel nanoparticle formulation of epirubicin that has a pH sensitive linker conjugated to epirubicin. It exhibits selective tumor accumulation owing to enhanced permeability and retention effect. We conducted a phase 1b trial to determine maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of NC-6300 monotherapy in advanced, metastatic, or unresectable solid tumors, including soft tissue sarcomas. Experimental Design: This Phase 1b dose escalation trial of NC-6300...
Thu May 07, 2020 16:09
Purpose: Colorectal cancer (CRC) patients with peritoneal metastases (CRPM) have limited treatment options and the lowest CRC survival rates. We aimed to determine whether organoid testing could help guide precision treatment for CRPM patients, as the clinical utility of prospective, functional drug screening including non-standard agents is unknown. Experimental Design: CRPM organoids (peritonoids) isolated from patients underwent parallel next-generation sequencing and medium-throughput drug panel...
Wed May 06, 2020 16:35
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Purpose:Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; "tavo") electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL).Patients and Methods:Tavo was administered intratumorally days 1, 5, and 8 every...
Wed May 06, 2020 10:05
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου